In this second part, we continue our look at sulbutiamine, a molecule that has circulated for decades, straddling the line between clinical pharmacology and the culture of so-called smart drugs. Far from the enthusiasm found in online forums, the interesting work lies in separating what is reasonably documented from what remains conjecture.
From Vitamin B1 to a Molecule That Reaches the Brain
Thiamine, or vitamin B1, is essential for the energy metabolism of neurons, but its natural form crosses the barrier protecting the brain poorly. Sulbutiamine was created precisely to solve this problem: it is a lipid-soluble derivative designed to penetrate nervous tissue more effectively. After oral administration, it is absorbed rapidly, reaches its maximum concentration in about one to two hours, and has a short half-life of approximately five hours. It is one of the few compounds in this family described as capable of acting selectively in brain regions associated with asthenia.
It is worth highlighting a nuance that is often omitted: the exact mechanism of action is not fully understood. Hypotheses point to circuits related to arousal (physiological and psychological activation), attention, motivation, and memory, involving cholinergic, dopaminergic, and glutamatergic systems. However, “it is postulated to act on” is not the same as “it has been proven to act this way.”
What Is Asthenia and Why Does It Matter Here?
The word asthenia comes from the Greek (a, “not,” and sthénos, “vigor”) and describes a persistent feeling of fatigue, weakness, and a lack of energy and motivation that accompanies numerous disorders. It manifests physically—as continuous tiredness—and mentally—as a decline in concentration and memory. In more severe contexts, it can be associated with anxiety, low mood, or a loss of sexual desire. Much of the asthenia we see today has no clear organic cause but is instead related to sustained stress and depressive states, something the current pace of life does not help improve.
This point is important because sulbutiamine has been tested primarily as a treatment for asthenia, not as a cognitive enhancer for healthy individuals. Extrapolating these clinical results to recreational or “performance” use is a leap that the evidence does not clearly support.
What Studies on Asthenia Show
Several publications describe symptomatic relief of asthenia with sulbutiamine. The prevailing explanation is that it reinforces the activity of the reticular activating system—the structure linked to alertness—and increases the density of acetylcholine receptors, resulting in a feeling of increased energy and concentration.
A frequently cited study (Vein et al., 2003) administered the compound for four weeks to a group of patients with psychovegetative syndrome and marked asthenia, describing a notable reduction in symptoms and an improvement in psychometric indices, with good tolerance. Such results are encouraging, but they must be read with caution: small sample sizes, absence or weakness of blinding, subjective improvement criteria, and, in general, a scattered and dated body of literature. A preliminary signal is not the same as established clinical efficacy.
Memory and “Intellectual Performance”: Between Promise and the Mouse
The idea that sulbutiamine improves memory comes partly from animal studies. In rodents, improved performance has been described in conditioning and object recognition tests (Micheau et al.), attributed to its effect on cholinergic transmission. The classic problem of nootropic research reappears here: what works in a mouse does not automatically translate to a person, much less a healthy person without a prior deficit.
In the clinical field, an early-phase trial for Alzheimer’s disease (Ollat et al.) explored combining sulbutiamine with donepezil, an anticholinesterase drug, describing an improvement in episodic memory and daily activities compared to donepezil plus a placebo. This is interesting data, but it is limited to a very specific pathological context and a base treatment; it does not authorize its presentation as a general-purpose cognitive enhancer.
Psychogenic Erectile Dysfunction
Some studies, mostly of Russian origin and with limited methodology, have described favorable effects of sulbutiamine in men with psychogenic erectile dysfunction. Given that the emotional and fatigue components weigh heavily in these cases, it fits with its anti-asthenic profile. Even so, the quality of the evidence is modest and does not allow for firm recommendations.
Availability and Status
Sulbutiamine is commonly sold in tablets and is a legal medication in Spain and several Latin American countries, where it is usually inexpensive. In this article, we do not cite brand names or dosage guidelines: that is what the package insert, the medical reference guide, and, above all, consultation with a healthcare professional are for. Our intention is to inform, not to guide purchases or consumption.
Critical Reading and Harm Reduction
Just because a substance is “mild” and legal does not make it harmless or miraculous. It is worth keeping several things in mind:
- The evidence is limited. Much of the research is old, small, or methodologically fragile, and many studies focus on patients with asthenia, not healthy people looking to “perform better.”
- It is not a substitute for a diagnosis. Persistent fatigue can hide anemia, thyroid problems, sleep apnea, depression, or other causes that require medical attention. Self-medicating to mask the symptom can delay real treatment.
- It has contraindications. It is discouraged for people with anxiety or insomnia and for those with particularly nervous temperaments. Reported adverse effects include skin reactions and agitation, which usually subside upon discontinuation.
- Beware of the placebo effect and initial euphoria. Subjective improvement in the first few days does not demonstrate sustained efficacy; one should be wary of tolerance and continued use without supervision.
In short, sulbutiamine is an interesting and reasonably well-tolerated molecule, with some support for the treatment of asthenia and a nootropic profile that is much more suggested than proven. Treating it as what it is—a drug with specific indications and still-incomplete evidence—is the most sensible attitude to take against the mythology surrounding it on the internet.
